Sintilimab, stereotactic body radiotherapy and granulocyte-macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial.
Jianjiao NiYue ZhouLin WuXinghao AiXiaorong DongQian ChuChengbo HanXiaofei WangZhengfei ZhuPublished in: Radiation oncology (London, England) (2021)
Sintilimab, SBRT and GM-CSF for advanced NSCLC is safe with manageable TRAEs and the trial continues to recruit participants. Trial registration ClinicalTrials.gov, NCT04106180. Registered 26 September 2019, SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC-Tabular View-ClinicalTrials.gov.
Keyphrases
- advanced non small cell lung cancer
- radiation therapy
- epidermal growth factor receptor
- phase iii
- study protocol
- phase ii
- clinical trial
- open label
- small cell lung cancer
- early stage
- adipose tissue
- radiation induced
- locally advanced
- tyrosine kinase
- double blind
- randomized controlled trial
- cross sectional
- placebo controlled